Weekly Appellate Report Podcast interviews Ben Davidson to explain
fallout from Supreme Court’s decision limiting venue for patent infringement
lawsuits
www.dailyjournal.com/podcast/?eid=957881
www.dailyjournal.com/podcast/?eid=957881
AIA Review #
|
Filing Date
|
Institution Decision Date
|
Petitioner
|
PO/Respondent Patent #
|
PO/Respondent
|
Status
|
Blog Notes
|
IPR2015-01624
|
07/27/2015
|
02/05/2016
|
Sanofi-Aventis U.S. LLC
|
6331415
|
Genentech, Inc.
|
Terminated
|
Genentech settled after the
institution of the IPR.
|
IPR2016-00383
|
12/30/2015
|
06/23/2016
|
GENZYME CORPORATION
|
6331415
|
Genentech Inc.
|
Terminated
|
The IPR petition was denied.
|
IPR2016-00460
|
01/15/2016
|
06/08/2016
|
Genzyme Corporation
|
6331415
|
GENENTECH, INC.
|
Terminated
|
Genentech settled after the institution
of the IPR.
|
IPR2016-00710
|
03/03/2016
|
09/08/2016
|
Mylan Pharmaceuticals Inc.
|
6331415
|
Genentech, Inc.
|
Terminated
|
Genentech settled after the
institution of the IPR.
|
IPR2016-01373
|
07/07/2016
|
01/03/2017
|
Merck Sharp & Dohme Corp.
|
6331415
|
Genentech, Inc.
|
Institution Denied
|
The IPR petition was denied.
|
IPR2017-00047
|
10/11/2016
|
01/03/2017
|
Merck Sharp & Dohme Corp.
|
6331415
|
Genentech, Inc.
|
Terminated
|
Genentech settled after the
institution of the IPR.
|
Patent Number/IPR
|
Claim 1
|
8,557,244
IPR2017-01166
|
1. A method of
treating a patient with diffuse large cell lymphoma, comprising administering
an unlabeled chimeric anti-CD20 antibody and CHOP (cyclophosphamide,
hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone)
chemotherapy to the patient, wherein the patient is >60 years old and has
bulky disease (tumor >10 cm in diameter).
|
8,329,172
IPR2017-01167
|
1. A method of
treating low grade B-cell non-Hodgkin's lymphoma in a human patient
comprising administering to the patient chemotherapy consisting of CVP
therapy to which the patient responds, followed by rituximab maintenance
therapy, wherein the maintenance therapy comprises four weekly
administrations of rituximab at a dose of 375 mg/m.2 every 6
months, and wherein the maintenance therapy is provided for 2 years.
|
9,296,821
IPR2017-01095
Filed by Celltrion but not Pfizer
|
1. A method for
treating low grade or follicular non-Hodgkin's lymphoma (NHL) comprising
administering to a patient a therapeutically effective amount of rituximab
during a chemotherapeutic regimen, wherein the chemotherapeutic regimen
consists of cyclophosphamide, vincristine, and prednisone (CVP therapy),
wherein the method comprises administering 375 mg/m2 of
rituximab, and wherein the method provides a beneficial synergistic effect in
the patient.
|
AIA Review #
|
Filing Date
|
Institution Decision Date
|
Petitioner
|
PO/Respondent Patent #
|
Respondent
|
Status
|
|||
IPR2015-00418
|
12/15/2014
|
07/13/2015
|
Boehringer
Ingelheim Pharmaceuticals, Inc.
|
8329172
|
Biogen
Inc.
|
Terminated
|
|||
IPR2017-01093
|
03/15/2017
|
Celltrion
Inc.
|
8329172
|
Biogen,
Inc.
|
Pending
|
||||
IPR2017-01166
|
04/21/2017
|
Pfizer,
Inc.
|
8329172
|
Pending
|
|||||
IPR2017-01094
|
03/15/2017
|
Celltrion Inc.
|
8557244
|
Biogen, Inc.
|
Pending
|
||||
IPR2017-01167
|
04/27/2017
|
Pfizer, Inc.
|
8557244
|
Pending
|
|||||
7,582,727
|
Pharmaceutical
batches of a drug product comprising bivalirudin (SEQ ID NO: 1) and a
pharmaceutically acceptable carrier for use as an anticoagulant in a subject
in need thereof, wherein the batches have a pH adjusted by a base, said pH is
about 5-6 when reconstituted in an aqueous solution for injection, and wherein the batches have a maximum
impurity level of Asp9-bivalirudin that does not exceed about 0.6%
as measured by HPLC.
|
7,598,343
|
1. Pharmaceutical batches of a drug product
comprising bivalirudin (SEQ ID NO: 1) and a pharmaceutically acceptable
carrier, for use as an anticoagulant in a subject in need thereof, said
batches prepared by a compounding process comprising: (i) dissolving
bivalirudin in a solvent to form a first solution; (ii) efficiently mixing a pH-adjusting solution with the first solution to
form a second solution, wherein the pH-adjusting solution comprises a
pH-adjusting solution solvent; and (iii) removing the solvent and
pH-adjusting solution solvent from the second solution; wherein the batches
have a pH adjusted by a base, said pH is about 5-6 when reconstituted in an
aqueous solution for injection, and
wherein the batches have a maximum impurity level of Asp9-bivalirudin
that does not exceed about 0.6% as measured by HPLC.
|